Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.

Journal Article (Journal Article)

Sexual transmission of human immunodeficiency virus type 1 (HIV-1) most often results from productive infection by a single transmitted/founder (T/F) virus, indicating a stringent mucosal bottleneck. Understanding the viral traits that overcome this bottleneck could have important implications for HIV-1 vaccine design and other prevention strategies. Most T/F viruses use CCR5 to infect target cells and some encode envelope glycoproteins (Envs) that contain fewer potential N-linked glycosylation sites and shorter V1/V2 variable loops than Envs from chronic viruses. Moreover, it has been reported that the gp120 subunits of certain transmitted Envs bind to the gut-homing integrin α4β7, possibly enhancing virus entry and cell-to-cell spread. Here we sought to determine whether subtype C T/F viruses, which are responsible for the majority of new HIV-1 infections worldwide, share biological properties that increase their transmission fitness, including preferential α4β7 engagement. Using single genome amplification, we generated panels of both T/F (n = 20) and chronic (n = 20) Env constructs as well as full-length T/F (n = 6) and chronic (n = 4) infectious molecular clones (IMCs). We found that T/F and chronic control Envs were indistinguishable in the efficiency with which they used CD4 and CCR5. Both groups of Envs also exhibited the same CD4+ T cell subset tropism and showed similar sensitivity to neutralization by CD4 binding site (CD4bs) antibodies. Finally, saturating concentrations of anti-α4β7 antibodies failed to inhibit infection and replication of T/F as well as chronic control viruses, although the growth of the tissue culture-adapted strain SF162 was modestly impaired. These results indicate that the population bottleneck associated with mucosal HIV-1 acquisition is not due to the selection of T/F viruses that use α4β7, CD4 or CCR5 more efficiently.

Full Text

Duke Authors

Cited Authors

  • Parrish, NF; Wilen, CB; Banks, LB; Iyer, SS; Pfaff, JM; Salazar-Gonzalez, JF; Salazar, MG; Decker, JM; Parrish, EH; Berg, A; Hopper, J; Hora, B; Kumar, A; Mahlokozera, T; Yuan, S; Coleman, C; Vermeulen, M; Ding, H; Ochsenbauer, C; Tilton, JC; Permar, SR; Kappes, JC; Betts, MR; Busch, MP; Gao, F; Montefiori, D; Haynes, BF; Shaw, GM; Hahn, BH; Doms, RW

Published Date

  • 2012

Published In

Volume / Issue

  • 8 / 5

Start / End Page

  • e1002686 -

PubMed ID

  • 22693444

Pubmed Central ID

  • PMC3364951

Electronic International Standard Serial Number (EISSN)

  • 1553-7374

Digital Object Identifier (DOI)

  • 10.1371/journal.ppat.1002686


  • eng

Conference Location

  • United States